<DOC>
	<DOCNO>NCT00076934</DOCNO>
	<brief_summary>Multiple sclerosis ( MS ) autoimmune disorder . In disease , body 's immune system attack destroy cell cover protect nerve . This study test safety new drug call RG2077 design treat MS . The study determine whether RG2077 effective treating MS , whether safe use patient MS. Study hypothesis : RG2077 arrest MS administer early course MS decrease accumulation lesion MRI .</brief_summary>
	<brief_title>Safety RG2077 Patients With Multiple Sclerosis</brief_title>
	<detailed_description>Effective treatment autoimmune disorder likely arise improve immunosuppression , improve understanding normal mechanism generate maintain self-tolerance . RG2077 may block T cell costimulation pathway central pathophysiology MS. A total 20 patient MS enrol study . Each patient participate study 4 month . The dose-escalation portion study evaluate safety single infusion RG2077 ( CTLA4-IgG4m ) 16 patient MS complete . Patients participate single infusion portion study assign one four group . Each group receive different dose RG2077 . The second portion study evaluate safety 4 dos RG2077 4 additional patient . In multiple infusion portion study , patient receive dose RG2077 . Patients monitor possible side effect RG2077 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion Criteria Confirmed diagnosis MS , define MRI consistent MS plus two separate clinical event , one clinical event MRI consistent demyelination plus second MRI demonstrate new lesion Have decline FDA approve therapy MS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ataxia</keyword>
	<keyword>MRI</keyword>
	<keyword>MS</keyword>
	<keyword>CTLA4-IgG4m</keyword>
	<keyword>Costimulatory Signals</keyword>
	<keyword>Autoimmune Disorders</keyword>
</DOC>